PharmaCielo (PCLO) Stock Overview
Together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PCLO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PharmaCielo Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.045 |
| 52 Week High | CA$0.23 |
| 52 Week Low | CA$0.025 |
| Beta | 1.76 |
| 1 Month Change | 0% |
| 3 Month Change | -35.71% |
| 1 Year Change | -59.09% |
| 3 Year Change | -88.75% |
| 5 Year Change | -90.91% |
| Change since IPO | -99.23% |
Recent News & Updates
Recent updates
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?
Oct 04
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?
Feb 25PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt
Aug 03Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?
Dec 23Is PharmaCielo (CVE:PCLO) A Risky Investment?
May 14Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?
Feb 16Shareholder Returns
| PCLO | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | -7.7% | 0.9% |
| 1Y | -59.1% | -24.7% | 21.0% |
Return vs Industry: PCLO underperformed the Canadian Pharmaceuticals industry which returned -24.7% over the past year.
Return vs Market: PCLO underperformed the Canadian Market which returned 21% over the past year.
Price Volatility
| PCLO volatility | |
|---|---|
| PCLO Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.5% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine PCLO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Marc Lustig | www.pharmacielo.com |
PharmaCielo Ltd., together with its subsidiary, engages in cultivating, processing, and supplying medicinal-grade cannabis extracts in Canada. Its products include medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol and cannabidiol medical cannabis, and other cannabis related products, as well as provides telemedicine software. The company also exports its products.
PharmaCielo Ltd. Fundamentals Summary
| PCLO fundamental statistics | |
|---|---|
| Market cap | CA$8.46m |
| Earnings (TTM) | -CA$9.14m |
| Revenue (TTM) | CA$3.48m |
Is PCLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCLO income statement (TTM) | |
|---|---|
| Revenue | CA$3.48m |
| Cost of Revenue | CA$2.75m |
| Gross Profit | CA$730.88k |
| Other Expenses | CA$9.87m |
| Earnings | -CA$9.14m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 21.00% |
| Net Profit Margin | -262.70% |
| Debt/Equity Ratio | -273.1% |
How did PCLO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/14 14:08 |
| End of Day Share Price | 2025/08/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaCielo Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Stifel Canada |
| Robert Fagan | Stifel Canada |